Skip to content
★ Sign in to follow
Nephro Care India Limited logo

Nephro Care India Limited Stock: price and insider trades · India

IN·Mcap ₹65.9B

No insider purchase over the last 90 days. The latest, by Ranita Bose, was filed 28 Mar 2026.

Nephro Care India Limited: what insiders have been doing

This page follows insider dealings at Nephro Care India Limited as filed with SEBI (PIT + SAST). In the past year (10 November 2025 to 10 November 2026), 2 filings came from 2 insiders.

The flow runs one way only: 2 insiders bought (2 purchases totalling €28k) and nobody sold on the market. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 1 senior executive among the declarants. One trade stands out by size: a purchase of €23k from Ranita Bose, disclosed on 28 March 2026.

Within a 30-day window, 2 purchases overlapped with buying by a second insider. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The latest purchase dates back some time: it was published 227 days ago, on 28 March 2026.

Across the 1,986 companies tracked on its exchange, the median is 4 filings; at 2 filings, this issuer sits below that mark. Looking back to 2026, when coverage begins, insiders filed 2 purchases and no sales.

Source: insider filings from SEBI (PIT + SAST). Past trades are no guide to future returns.

Insider Decl.
2
Thresholds
n/a
Buy Volume
€28,254
2 ops. · all time
Sell Volume
n/a
n/a

Who traded when

BuySale
Ranita Bose1 buy
Tapas Saha1 buy

Since the insiders bought

  • Filed 28 Mar 2026 · 227 days ago · €5,054
    +22.7%
    Entry ₹505.55 · Close 13 Oct 2026 ₹620.15
  • Filed 28 Mar 2026 · 227 days ago · €23k
    +22.7%
    Entry ₹505.55 · Close 13 Oct 2026 ₹620.15

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 12,834 of 26,911 companies
52.7
score / 100
Value
34
Quality
71
FCF yld1.8%
Earn yld1.2%
EV/EBITDA25.4x
ROE9.0%
Gross mgn58%
Net mgn7.7%
Debt/EBITDA0.3x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2026

FY ended March 2026 · cache

₹655.00
Analyst consensus
4 analysts
1.50/5
₹780.00Target ₹847.50(+29%)₹1,000.00
Income statement
Revenue₹9.9B
Gross profit₹5.8B58% margin
EBITDA₹2.4B25% margin
Net income₹768.4M8.1% margin
Valuation
PER (trailing)77.2x
PER (forward)31.0x
P/Book5.9x
Balance sheet & cash
Market cap₹65.9B
Total debt₹797.1M
Free Cash Flow₹1.1B
Debt / Equity7%
Profitability & ownership
ROE9.0%
ROA7.0%
% insiders49.3%
% institutions38.5%
Last declaration on 28 March 2026
Declarations2 total
  • ▲
    Key Managerial PersonnelExecutives
    541,800 INR31SEBI
    9,600 shares@ ₹56.4375100.0% of flowEquity SharesSEBI:b27201033303eb2e15b23192b884e96a0ccd26af
    Canonical exit: 7 Jun 2026 (T+90)
  • ▲
    Immediate relativeExecutives
    2M INR22SEBI
    35,200 shares@ ₹70.9545100.0% of flowEquity SharesSEBI:fead4963d7d78da70a8c8969521a67b945121468
    Canonical exit: 18 May 2026 (T+90)

2 of 2 declarations

About Nephro Care India Limited

Nephro Care India Limited is a company specializing in nephrology care in India. It provides dialysis services and treatment for kidney diseases.